Sanofi (SNY) Lowered to Underweight at Barclays

Sanofi (NYSE:SNY) was downgraded by equities research analysts at Barclays from an “equal weight” rating to an “underweight” rating in a note issued to investors on Tuesday.

SNY has been the topic of several other reports. UBS Group reaffirmed a “neutral” rating on shares of Sanofi in a research report on Monday, January 15th. Bank of America downgraded Sanofi from a “buy” rating to a “neutral” rating in a research report on Wednesday, December 6th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a research report on Thursday, December 14th. Zacks Investment Research downgraded Sanofi from a “hold” rating to a “strong sell” rating in a research report on Friday, October 6th. Finally, Cowen set a $48.00 price target on Sanofi and gave the stock a “hold” rating in a research report on Monday, December 18th. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and two have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $51.50.

Shares of Sanofi (SNY) traded up $0.58 during midday trading on Tuesday, reaching $43.79. The company’s stock had a trading volume of 604,539 shares, compared to its average volume of 1,968,993. The company has a current ratio of 1.59, a quick ratio of 1.16 and a debt-to-equity ratio of 0.26. The company has a market cap of $109,330.00, a P/E ratio of 19.81, a P/E/G ratio of 2.43 and a beta of 0.86. Sanofi has a 52 week low of $39.42 and a 52 week high of $50.65.

Sanofi (NYSE:SNY) last issued its quarterly earnings results on Thursday, November 2nd. The company reported $1.00 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $1.00. The company had revenue of $10.63 billion for the quarter, compared to the consensus estimate of $10.93 billion. Sanofi had a return on equity of 25.19% and a net margin of 25.44%. sell-side analysts expect that Sanofi will post 3.34 earnings per share for the current year.

Several large investors have recently made changes to their positions in SNY. Bank of Nova Scotia Trust Co. acquired a new stake in shares of Sanofi during the 3rd quarter worth approximately $125,000. YorkBridge Wealth Partners LLC grew its holdings in shares of Sanofi by 33.7% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 3,076 shares of the company’s stock worth $147,000 after purchasing an additional 776 shares in the last quarter. Toronto Dominion Bank grew its holdings in shares of Sanofi by 4.6% during the 2nd quarter. Toronto Dominion Bank now owns 4,054 shares of the company’s stock worth $195,000 after purchasing an additional 180 shares in the last quarter. Mraz Amerine & Associates Inc. acquired a new stake in shares of Sanofi during the 3rd quarter worth approximately $204,000. Finally, River Road Asset Management LLC acquired a new stake in shares of Sanofi during the 3rd quarter worth approximately $208,000. 9.07% of the stock is currently owned by institutional investors.

WARNING: This article was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/01/23/barclays-reiterates-underweight-rating-for-sanofi-sny.html.

About Sanofi

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply